Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Vaxcyte, Inc. Market Cap
From what 0 stock analysts predict, the share price for Vaxcyte, Inc. (PCVX) might decrease by 11.06% in the next year. This is based on a 12-month average estimation for PCVX. Price targets go from $95 to $113. The majority of stock analysts believe PCVX is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
Vaxcyte, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Vaxcyte, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of PCVX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Stringer Needham | Buy | $95 | Reiterates | Aug 7, 2024 |
| Joseph Stringer Needham | Buy | $95 | Reiterates | Jun 28, 2024 |
| Louise Chen Cantor Fitzgerald | Overweight | Reiterates | Jun 20, 2024 | |
| Joseph Stringer Needham | Buy | $95 | Reiterates | May 9, 2024 |
| Louise Chen Cantor Fitzgerald | Overweight | Reiterates | May 9, 2024 | |
| Joseph Stringer Needham | Buy | $95 | Reiterates | Apr 10, 2024 |
| Salim Syed Mizuho | Buy | $113 | Maintains | Mar 12, 2024 |
| Joseph Stringer Needham | Buy | $95 | Maintains | Feb 28, 2024 |
| Jason Gerberry B of A Securities | Buy | $80 | Maintains | Jan 2, 2024 |
| Salim Syed Mizuho | Buy | $69 | Initiates | Dec 7, 2023 |
| Joseph Stringer Needham | Buy | $58 | Reiterates | Nov 7, 2023 |
| Louise Chen Cantor Fitzgerald | Overweight | $70 | Reiterates | Aug 22, 2023 |
Needham | Buy | Reiterates | Aug 9, 2023 | |
| Joseph Stringer Needham | Buy | $58 | Reiterates | May 9, 2023 |
| Boris Peaker TD Cowen | Outperform | Initiates | Apr 18, 2023 | |
| Jason Gerberry B of A Securities | Buy | $68 | Maintains | Apr 18, 2023 |
Cantor Fitzgerald | Overweight | Maintains | Mar 1, 2023 | |
| Seamus Fernandez Guggenheim | Buy | $65 | Maintains | Feb 28, 2023 |
| Joseph Stringer Needham | Buy | $58 | Reiterates | Feb 28, 2023 |
| Joseph Stringer Needham | Buy | $58 | Maintains | Jan 3, 2023 |
When did it IPO
2020
Staff Count
254
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Grant E. Pickering M.B.A.
Market Cap
$8.79B
In 2023, PCVX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that PCVX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 11 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Vaxcyte, Inc. (Nasdaq: PCVX) will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on September 18 at 10:20 a.m. ET.
Why It Matters - Vaxcyte's participation in a prominent healthcare conference may indicate potential investor interest and market visibility, influencing stock performance and future funding opportunities.
Sun, 08 Sep 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Vaxcyte's XpressCF platform advances broad-spectrum vaccines. VAX-31 shows promising Phase 1/2 results, targeting invasive pneumococcal disease, with Phase 3 trials set for mid-2025.
Why It Matters - Vaxcyte's advancements in broad-spectrum vaccines and promising Phase 1/2 results for VAX-31 enhance its competitive edge, potentially driving significant future revenue and market share growth.
Thu, 05 Sep 2024
Sentiment - POSITIVE
Source - Reuters
Summary - Vaxcyte plans to raise $1.3 billion through the sale of common stock and warrants, following a surge in shares due to positive results from a vaccine trial.
Why It Matters - Vaxcyte's $1.3 billion capital raise signals strong investor confidence and funds for further development, potentially enhancing growth prospects and share value.
Fri, 06 Sep 2024
Sentiment - NEGATIVE
Source - Market Watch
Summary - Vaxcyte Inc. shares dropped 3% after the company announced a completed stock offering projected to raise $1.42 billion.
Why It Matters - The stock decline indicates market skepticism about dilution from the offering, despite the significant capital raised, impacting investor sentiment and future valuation.
Wed, 04 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - PCVX's pneumococcal vaccine shows promising immune responses comparable to those of Pfizer and Merck's marketed vaccines, according to early-stage study data.
Why It Matters - PCVX's pneumococcal vaccine showing strong immune responses suggests competitive potential in the market, which could impact its stock value and attract investor interest.
Wed, 04 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Vaxcyte, Inc. announced a public offering of 10,194,175 shares at $103 each and pre-funded warrants at $102.999, aiming for $1.3 billion in gross proceeds.
Why It Matters - Vaxcyte's $1.3 billion stock offering indicates strong financial backing, which can enhance growth potential. Investors may view this as a signal of confidence in the company's future prospects.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
